Physician profile
George A Moninger
NPI 1316924699
$4,688.68
in general payments reported to CMS, 2019-2025
25 companies · $917 in 2025
The $917 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $458 · 2021: $320 · 2022: $591 · 2023: $721 · 2024: $1,226 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $964.17 | 2019-2025 | Clareon, Argos, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $761.30 | 2022-2025 | |
| Allergan, INC. | $362.98 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $330.33 | 2019-2021 | |
| Glaukos Corporation | $326.07 | 2020-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $318.93 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $213.11 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $177.56 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $170.18 | 2019-2024 | Veritas Vision System, Tecnis Iol |
| Rxsight INC | $147.79 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Horizon Therapeutics Plc | $141.08 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $133.53 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $120.89 | 2019-2023 | |
| Biotissue Holdings INC. | $91.73 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $89.73 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $63.46 | 2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $59.78 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $43.30 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $42.47 | 2023-2024 | Vevye |
| Kala Pharmaceuticals, INC. | $38.51 | 2019 | |
| Avanos Medical | $19.26 | 2021 | |
| Akorn, INC. | $19.11 | 2020 | |
| Shire North American Group INC | $18.38 | 2019 | |
| Rayner Intraocular Lenses Limited | $17.91 | 2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $17.12 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Moninger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.